Back to Newsroom
Back to Newsroom

RAMO Bio-Med, Inc. Commences With Research on Charlottes Web or AC/DC Cultivation and Genetic Molecular Engineering

Thursday, 02 October 2014 11:59 AM

Ramoil Management, Ltd.

Topic:

Ramoil Management, Ltd., Thursday, October 2, 2014, Press release picture 

Las Vegas, NV / ACCESSWIRE / October 2, 2014 / RAMOIL MANAGEMENT, Ltd (OTC Pink: RAMO) (PINKSHEETS: RAMO), would like to announce that it has begun research on the Charlottes Web or AC/DC cannabis strain, regarding cultivation and genetic engineering or manipulation.

RAMO Bio-Med, Inc. has acquired and planted sufficient seedlings of the strain AC/DC, a.k.a. Charlottes Web. Within 2 weeks, our scientist will begin to genetically engineer these clones and strain to increase the CBD % over 25% and reduce the THC % below 0.05% and ideally at or under 0.03% THC. Essentially, maximizing the CBD percentage and minimizing the THC percentage of this strain is our goal.

Finally, the RAMO Bio-Med in-house Scientists will increase the AC/DC or Charlottes Web clones' yield potential more than 20%, to maximize the plant production or yield (output).

Michael Goeree, Ramoil Management's Chairman, President and Chief Executive Officer, said, "It took some time to secure proper strains of AC/DC or Charlottes Web clones for research and genetic engineering. This will become the basis of our CBD based Medicine Production both here in America, as well as internationally."

Mr. Goeree further stated, "It is always a great day when the cornerstone of any structure is secured and set into place."

About Ramoil Management, Ltd.

Ramoil Management, Ltd. (RAMO) is a development stage company. The Company is an online wholesaler of E-cigarettes containing nutraceutical vapor oils, E-cigarette delivery systems and hydroponic lighting and nutrients.

About RAMO Bio-Med, Inc.

RAMO Bio-Med, Inc. is a wholly owned subsidiary of Ramoil Management, Ltd. (RAMO) and is a development stage company. The Company is the operating company of the newly acquired "Supercritical CO2 Molecular Extraction Technology" and will be building operating production facilities and research labs, both domestically and internationally, focused on its own proprietary strain of High CBD Extremely Low THC "Charlottes Webb" and Extraction Facilities (Labs and Manufacturing), for the development, production and sales of CBD extractions, concentrates and medicines.

Forward Looking Statements:

This news release contains forward-looking statements made by RAMOIL MANAGEMENT, LTD. All such statements included in this press release, other than statements of historical fact, are forward-looking statements. Although management believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Actual results may differ materially from those indicated by these statements. The following risk factors, among others, could cause actual results to differ materially from those described in any forward-looking statements. These risks and uncertainties include, but are not limited to, economic conditions, changes in the law or regulations, demand for products of the Company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward looking statements. Forward-looking statements are typically identified by the words: believe, expect, anticipate, intend, estimate, and similar expressions or which by their nature refer to future events. The Company is not entitled to rely on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 because it is not registered under either Act.

CONTACT:

Company and Investor Relations Contact:

Frank Blainey, Esq.

+1-702-381-1961

[email protected]

SOURCE: Ramoil Management, Ltd. 

Topic:
Back to newsroom
Back to Newsroom
Share by: